Glen Clova Scientific

About

Glen Clova Scientific (GCS) is developing a new class of therapeutic vaccines targeting dermatological and allergic conditions. Using Virus-Like Particles (VLPs), GCS harnesses the body’s immune system to neutralise key disease-driving proteins, offering a fundamentally different approach to treatment. This platform enables highly targeted intervention with significantly reduced dosing, typically one or two administrations per year, without the need for ongoing medication or routine monitoring. The result is a more practical and potentially more effective alternative to conventional therapies. GCS’ first indication is Canine Atopic Dermatitis, where the company is making strong progress within the veterinary pharmaceutical market. This provides a clear route to early commercialisation while building the foundation for broader application in human conditions, including asthma, eczema and other allergic diseases. Built on more than a decade of research, GCS is advancing a platform with t